Results 21 to 30 of about 3,260 (169)

Eltrombopag Use for Treatment of Thrombocytopenia in a Patient with Chronic Liver Disease and Portal Vein Thrombosis: Case Report

Case Reports in Oncology, 2020
Off-label drug use refers to drug use beyond the specifications authorized for marketing [J Med Case Rep. 2014 Dec;8(1):303]. Eltrombopag is a thrombopoietin receptor agonist that has been used in treating thrombocytopenia due to chronic liver disease ...
Sabah E. Mohamed, Mohamed A. Yassin
doaj   +1 more source

The biology of thrombopoietin and thrombopoietin receptor agonists [PDF]

International Journal of Hematology, 2013
Thrombopoietin (TPO) is the major physiological regulator of platelet production. TPO binds the TPO receptor, activates JAK and STAT pathways, thus stimulating megakaryocyte growth and platelet production. There is no "sensor" of the platelet count; rather TPO is produced in the liver at a constant rate and cleared by TPO receptors on platelets.
openaire   +2 more sources

Development of thrombopoietin receptor agonists for clinical use [PDF]

Journal of Thrombosis and Haemostasis, 2009
Thrombopoietin (TPO) is an essential hematopoietic cytokine for megakaryopoiesis. In 2002, we demonstrated that pegylated-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts in patients with chronic immune thrombocytopenic purpura (ITP) in a Phase I/II clinical trial.
Y, Ikeda, Y, Miyakawa
openaire   +2 more sources

Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia [PDF]

Seminars in Hematology, 2013
Thrombopoietin (TPO) regulates thrombopoiesis through activation of TPO receptors on the megakaryocyte cell surface, resulting in increased platelet production. The TPO receptor agonists are novel treatments for patients with chronic ITP aimed at increasing platelet production through interactions with the TPO receptor on megakaryocytes.
Deborah, Siegal, Mark, Crowther, Adam, Cuker   +2 more
openaire   +2 more sources

Use of Thrombopoietin Receptor Agonists in Pregnancy

Hematology/Oncology and Stem Cell Therapy, 2022
The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids and intravenous immunoglobulin. With the emergence of novel therapies such as thrombopoietin receptor agonists (TPO-RAs), there has been a shift in treatment modalities.
Jude, Howaidi, Abdullah M, AlRajhi, Ali, Howaidi, Fouad H, AlNajjar, Imran K, Tailor   +4 more
openaire   +2 more sources

Clinical Indications for Thrombopoietin and Thrombopoietin-Receptor Agonists [PDF]

Transfusion Medicine and Hemotherapy, 2013
Thrombocytopenia is a common hematologic disorder. Stimulation of thrombopoiesis may reduce the risk for thrombocytopenia-induced bleeding, prevent severe thrombocytopenia, and reduce the need for platelet transfusion. The key cytokine is thrombopoietin (TPO).
openaire   +2 more sources

Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension

Platelets, 2022
Avatrombopag is an oral thrombopoietin receptor agonist approved for chronic immune thrombocytopenia (ITP). This is a post hoc analysis of the pivotal phase III study (NCT01438840) evaluating additional endpoints not previously described.
Hanny Al‐Samkari, Srikanth Nagalla
doaj   +1 more source

Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently

Frontiers in Cardiovascular Medicine, 2023
IntroductionThrombopoietin-receptor agonist (TPO-RAs) currently represent the state of art for treating immune thrombocytopenia. Their different molecular structures contribute to the difference in their pharmacodynamics and pharmacokinetics.
Mohamed A. Yassin, Mona Al-Rasheed, Murtadha Al-Khaboori, Mahmoud Marashi, Hani Osman, Yasser Wali, Salam Al Kindi, Faisal Alsayegh, Drew Provan   +8 more
doaj   +1 more source

Safety, tolerance, pharmacokinetic and pharmacodynamic properties of thrombopoietin mimetic peptide for injection in Chinese healthy volunteers: a randomized, placebo-controlled, double-blind study

Platelets, 2022
The thrombopoietin mimetic peptide for injection is a second-generation thrombopoietin receptor agonist (TPO-RA) used in the treatment of patients with immune thrombocytopenia.
Xiao-Yan Sheng, Zhi-Yan Liu, Jing Zhao, Lei Song, Wen-Ming Zhao, Xia Zhao, Yi-Min Cui   +6 more
doaj   +1 more source

Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report

Leukemia Research Reports
Patients who receive allogeneic hematopoietic stem cell transplantation (alloHSCT) are at risk for developing persistent thrombocytopenia. Here, we describe treatment with avatrombopag, a thrombopoietin receptor agonist, in a pediatric patient with ...
Emilie J. Lynch, Autumn Citta, Constance Alford, John A. Ligon, Mansi Dalal, Paul Castillo, Biljana Horn, Natalie Dotson, Giselle Moore-Higgs, Jordan Milner   +9 more
doaj   +1 more source